Study: Combining Brain Training and Walking Helps Heart Failure Patients
20 oct. 2020 08h00 HE
|
Posit Science
SAN FRANCISCO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- A new study from Emory University found a combined therapy of brain training and aerobic exercise improved multiple measures that drive better health...
Study: Brain Training for Heart Failure
25 févr. 2019 08h00 HE
|
Posit Science
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- A new study — made available online in advance of print by The American Journal of Geriatric Psychiatry and conducted by a team from Emory University...
Mesoblast Chairman's Address to 2015 Annual General Meeting
22 oct. 2015 02h00 HE
|
Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting.
This has been another exciting and productive year in the history of our...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
29 sept. 2015 21h10 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
16 août 2015 20h28 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
30 oct. 2013 18h41 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...